In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.
In Sub-studies 1 and 2, the effects of taking ziftomenib and other common drugs at the same time will be investigated in AML patients. In Sub-study 3, ziftomenib will be evaluated in patients with R/R acute lymphoblastic leukemia (ALL). In Sub-study 4, ziftomenib will be evaluated in patients with R/R AML with certain genetic mutations.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria:
Patients with refractory or relapsed AML defined as the reappearance of ≥ 5% blasts in the bone marrow and who have also failed or are ineligible for any approved standard of care therapies, including HSCT.
1. Phase 1b:
* Patients with a documented lysine\[K\]-specific methyltransferase 2-rearrangement (KMT2A-r), or
* Patients with a documented nucleophosmin 1 mutation (NPM1-m)
2. Phase 2:
* Patients with a documented nucleophosmin 1 mutation (NPM1-m)
3. Sub-studies:
* Sub-studies 1 and 2: Patients with R/R AML with NPM1-m or other mutations associated with MEIS1 overexpression.
* Sub-study 3: Patients with R/R Acute Lymphoblastic Leukemia (ALL) with KMT2A-r.
* Sub-study 4: Patients with R/R AML with mutations associated with MEIS1 overexpression.
4. ≥ 18 years of age.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and a life expectancy of at least 2 months.
6. Adequate liver and kidney function according to protocol requirements.
7. Peripheral white blood cell (WBC) counts ≤ 30,000/μL. Patients may receive hydroxyurea to control and maintain white blood cell count prior to enrollment.
8. Women of childbearing potential must be willing to use a highly effective method of contraception throughout the study and for at least 187 days after the last dose of study treatment.
9. Males with female partners of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 97 days after the last dose of study treatment.
Key Exclusion Criteria:
1. Diagnosis of acute promyelocytic leukemia.
2. Diagnosis of chronic myelogenous leukemia in blast crisis.
3. Donor lymphocyte infusion \< 30 days prior to study entry.
4. Clinically active central nervous system (CNS) leukemia.
5. Undergone HSCT and have not had adequate hematologic recovery.
6. Receiving immunosuppressive therapy post HSCT within 2 weeks of Cycle 1 Day 1.
7. Grade ≥ 2 active graft-versus-host disease (GVHD), moderate or severe limited chronic GVHD, or extensive chronic GVHD of any severity.
8. Received chemotherapy immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation) \< 14 days prior to the first dose of ziftomenib or within 5 drug half-lives prior to the first dose of study drug.
9. Not recovered to \< Grade 2 (National Cancer Institute Common Terminology Criteria for Adverse Events v5.0) from all acute toxicities or deemed back to a stable baseline.
10. Treatment with concomitant drugs that are strong inhibitors or inducers of cytochrome P450-isozyme 3A4 (CYP3A4), as follows:
* Phase 1a, 1b, 2, and sub-studies 3 and 4: with the exception of antibiotics, antifungals, and antivirals that are used as standard of care or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient.
* Sub-studies 1 and 2: No exceptions will be allowed except for the use of moderate CYP3A4 antifungal prophylaxis such as fluconazole or isavuconazole which is at steady state on Cycle 1 Day 1 and will continue through the completion of PKs on Cycle 1 Day 15 (for sub-study 1) or Cycle 1 Day 18 (for sub-study 2).
11. Detectable viral load for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen indicative of active infection. Patients with controlled disease will not be excluded from study enrollment.
12. Pre-existing disorder predisposing the patient to a serious or life-threatening infection (e.g. cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder, or cytopenias not related to AML).
13. Active uncontrolled acute or chronic systemic fungal, bacterial, viral, or other infection.
14. Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension or arrhythmia, history of cerebrovascular accident including transient ischemic attack within the past 6 months, congestive heart failure (NYHA Class III or IV) related to primary cardiac disease, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to the first dose of study treatment.
15. Mean QTcF \>480 ms on triplicate ECG.
16. Major surgery within 4 weeks prior to the first dose of study treatment.
17. Women who are pregnant or lactating. All female patients with reproductive potential must have a negative serum pregnancy test within 72 hours prior to starting treatment.
18. For sub-studies 1 and 2: Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of ziftomenib until the end of Cycle 1.
19. For sub-studies 1 and 2: Moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment.
Primary outcome measure(s)
Phase 1a: Maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) — Dose Limiting Toxicities (DLTs) will be evaluated during the first 28 days (1 cycle) MTD is defined as the highest dose that is not expected to cause dose limiting toxicity (DLT) in more than 20% of patients.
Phase 1b: Number of patients who experience Adverse Events (AEs) and Serious Adverse Events (SAEs) — During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first. Assessed by NCI-CTCAE v5.0
Phase 1b: Minimum biologically effective dose — For at least 12 months following end of treatment Minimum biologically effective dose in dosing cohorts which have demonstrated biological activity and have been determined to be safe as a part of Part 1a
Phase 1a, 1b, and 2: Evidence of anti-leukemia activity — For at least 12 months following end of treatment Assessed by the CR + CRh rate
Sub-study 1: Time to observed maximum plasma concentration (Tmax) of ziftomenib and midazolam — Cycle 1 on Days 1 and 15 at predose and postdose Tmax of ziftomenib, its metabolites, midazolam, and 1-hydroxymidazolam
Sub-study 1: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and midazolam — Cycle 1 on Days 1 and 15 at predose and postdose AUC0-t of ziftomenib, its metabolites, midazolam, and 1-hydroxymidazolam
Sub-study 1: Maximum observed plasma concentration (Cmax) of ziftomenib and midazolam — Cycle 1 on Days 1 and 15 at predose and postdose Cmax of ziftomenib, its metabolites, midazolam, and 1-hydroxymidazolam
Sub-study 2: Time to observed maximum plasma concentration (Tmax) of ziftomenib and itraconazole — Cycle 1 on Days 1, 15, and 22 at predose and postdose Tmax of ziftomenib, its metabolites, and itraconazole
Sub-study 2: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and itraconazole — Cycle 1 on Days 1, 15, and 22 at predose and postdose AUC0-t of ziftomenib, its metabolites, and itraconazole
Sub-study 2: Maximum observed plasma concentration (Cmax) of ziftomenib and itraconazole — Cycle 1 on Days 1, 15, and 22 at predose and postdose Cmax of ziftomenib, its metabolites, and itraconazole
Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D) — During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first Assessed by the number of patients that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) per NCI-CTCAE v5.0
Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D) — For at least 12 months following end of treatment Assessed by CR
Sub-study 3: Change in Eastern Cooperative Oncology Group (ECOG) status — Timeframe: from Baseline to End of Treatment To assess the change in ECOG status
Sub-study 3: Time to observed maximum plasma concentration (Tmax) of ziftomenib — Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards Tmax of ziftomenib
Sub-study 3: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib — Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards AUC0-t of ziftomenib
Sub-study 3: Maximum observed plasma concentration (Cmax) of ziftomenib — Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards. Cmax of ziftomenib
Sub-study 4: Complete remission (CR) and complete remission with partial hematologic recovery (CRh) — For at least 12 months following end of treatment To assess the CR+CRh rate
Trial sites (43)
Facility
City
Region
Status
Banner MD Anderson Cancer Center
Gilbert
Arizona
UCLA Ronald Reagan Medical Center
Los Angeles
California
Mayo Clinic
Jacksonville
Florida
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago
Illinois
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore
Maryland
Massachusetts General Hospital
Boston
Massachusetts
University of Michigan Hospitals
Ann Arbor
Michigan
Karmanos Cancer Institute
Detroit
Michigan
Mayo Clinic
Rochester
Minnesota
Hackensack University Medical Center - John Theurer Cancer Center
Hackensack
New Jersey
Roswell Park Comprehensive Cancer Center
Buffalo
New York
Weill Cornell Medical College - NY Presbyterian Hospital
New York
New York
The Mount Sinai Hospital
New York
New York
Duke Cancer Institute
Durham
North Carolina
Oklahoma University Health - Stephenson Cancer Center
Oklahoma City
Oklahoma
UPMC Hillman Cancer Center
Pittsburgh
Pennsylvania
Vanderbilt-Ingram Cancer Center
Nashville
Tennessee
Harold C. Simmons Comprehensive Cancer Center - UT Southwestern Medical Center
Dallas
Texas
MD Anderson Cancer Center
Houston
Texas
Fred Hutchinson Cancer Research Center
Seattle
Washington
AZ Delta - Campus Rumbeke
Roeselare
Belgium
Queen Elizabeth II Health Sciences Centre
Halifax
Nova Scotia
Hopital Maisonneuve-Rosemont
Montreal
Quebec
Hopital de l'Enfant-Jesus - Centre Integre en Cancerologie du CHU de Quebec - Universite Laval
Québec
Quebec
Centre Hospitalier Universitaire de Lille
Lille
France
Centre Hospitalier Universitaire de Nantes
Nantes
France
Hopital Saint Louis
Paris
France
Magendie Hopital Haut-Leveque
Pessac
France
Centre Hospitalier Lyon Sud
Pierre-Bénite
France
Institut Gustave Roussy
Villejuif
France
University Medicine Greifswald
Greifswald
Germany
Medizinische Hochsschule Hannover
Hanover
Germany
Institute of Hematology and Medical Oncology "L. and A. Seragnoli"
Bologna
Italy
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Meldola
Italy
UO Ematologia Ospedale di Ravenna
Ravenna
Italy
Institution Fondazione Policlinico Tor Vergata
Roma
Italy
Hospital Universitari Vall d'Hebron
Barcelona
Spain
Universitat de Barcelona
Barcelona
Spain
MD Anderson Cancer Center
Madrid
Spain
Hospital Universitario HM Sanchinarro
Madrid
Spain
+ 3 more sites — see the full list on the official registry below.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
